Comparison of thiazide-like diuretics versus thiazide-type diuretics: a meta-analysis

Wenjing Liang a, Hui Ma b, Luxi Cao c, Wenjiang Yan a, *, Jingjing Yang a, *

a The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, and The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Qilu Hospital of Shandong University, Jinan, Shandong, China

b Department of Pediatrics and Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China

c Kidney Disease Center, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Received: November 28, 2016; Accepted: March 23, 2017

Introduction

Thiazide diuretics were once the first effective oral antihypertensive agents with an acceptable side-effect profile. For more than a half-century, thiazide diuretics have been used for the management of hypertension [1]. Despite structural variation among the heterogeneous group of agents including the thiazide-type as well as thiazide-like diuretics, the term ‘thiazide diuretic’ incorporates all diuretics believed to have a primary action in the distal tubule [1]. The publication of 2014 ‘Evidence-Based Guideline for the

Keywords: thiazide-like diuretics & thiazide-type diuretics & hypertension & hypokalemia & hyponatremia

Abstract

Thiazide diuretics are widely used for the management of hypertension. In recent years, it has been actively debated that there is interchangeability of thiazide-type diuretics hydrochlorothiazide and thiazide-like diuretics including indapamide and chlorthalidone for the treatment of hypertension. With the purpose of seeking out the best thiazide diuretic for clinicians, we summarized the existing evidence on the two types of drugs and conducted a meta-analysis on their efficacy in lowering blood pressure and effects on blood electrolyte, glucose and total cholesterol. Twelve trials were identified: five based on the comparison of indapamide versus hydrochlorothiazide and seven based on the chlorthalidone versus hydrochlorothiazide. In the meta-analysis of blood pressure reduction, thiazide-like diuretics seemed to further reduce systolic BP ([95% CI]; 5.59 [5.69, 5.49]; P < 0.001) and diastolic BP ([95% CI]; –1.98 [3.29, –0.66]; P = 0.003). Meanwhile, in the analysis of side effects, the incidence of hypokalemia ([95% CI]; 1.58 [0.80, 3.12]; P = 0.19), hyponatremia ([95% CI]; –0.14 [–0.57, 0.30], P = 0.54), change of blood glucose ([95% CI]; 0.13 [–0.16, 0.41], P = 0.39) and total cholesterol ([95% CI]; 0.13 [–0.16, 0.41], P = 0.39) showed that there is no statistical significant differences between the two groups of drugs. In conclusion, using thiazide-like diuretics is superior to thiazide-type diuretics in reducing blood pressure without increasing the incidence of hypokalemia, hyponatremia and any change of blood glucose and serum total cholesterol.

Keywords: thiazide-like diuretics & thiazide-type diuretics & hypertension & hypokalemia & hyponatremia

Introduction

Thiazide diuretics were once the first effective oral antihypertensive agents with an acceptable side-effect profile. For more than a half-century, thiazide diuretics have been used for the management of hypertension [1]. Despite structural variation among the heterogeneous group of agents including the thiazide-type as well as thiazide-like diuretics, the term ‘thiazide diuretic’ incorporates all diuretics believed to have a primary action in the distal tubule [1]. The publication of 2014 ‘Evidence-Based Guideline for the
The half-life of HCTZ would suggest that the drug should be given twice daily. Compared to HCTZ, chlorthalidone has a longer half-life, almost 42 hr (range, 29–55 hr). At the same time, inspection of the available studies suggests that 50 mg HCTZ is approximately equivalent to 25–37 mg chlorthalidone. In other words, it suggests that equivalent doses of chlorthalidone should generally be 50–75% of typical HCTZ doses [5].

Both HCTZ and chlorthalidone have demonstrated cardiovascular events risk reduction in clinical trials. However, the largest trials, including the Systolic Hypertension in the Elderly Program (SHEP) study [6, 7], elaborated that only chlorthalidone can significantly lower rates of stroke as well as some other fatal or non-fatal cardiovascular events. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack (ALLHAT) study [8] that included over 30,000 hypertensive patients compared chlorthalidone to alpha-blockers, calcium channel blockers and ACE inhibitors. This randomized controlled trial demonstrated that at 12.5 and 25 mg/day dosages, chlorthalidone was beneficial in reducing new-onset heart failure compared with the other treatment used in the trial. Although there were strong evidence supporting the idea that chlorthalidone should be recommended as the initial treatment of hypertension, a study comparing these two types of diuretics directly is missing.

Indapamide, a member of thiazide-like agents, presents some differences with others. In fact, besides its diuretic properties, indapamide presents some protective effects on vascular or organ damage in animal and human investigations. In some clinical trials, it was effective in reducing left-ventricular mass index in hypertensive patients and remarkably improving the renal function [9]. Furthermore, in a recent large-scale RCT, use of a sustained-release indapamide-based regimen as initial therapy led to relative reductions of 39%, 64% and 21% in the rates of fatal stroke, heart failure and death, respectively, in patients older than 80 years of age [10]. Although much evidence demonstrated the effectiveness and advantages of indapamide, there is no large-scale immediate clinical trial and meta-analysis to evaluate the BP lowering efficacy and safety between indapamide and HCTZ.

To examine whether thiazide-like diuretics were superior over the thiazide-type diuretics in lowering blood pressure without affecting the biochemical properties, we undertook a meta-analysis of clinical trials with either HCTZ versus chlorthalidone or HCTZ versus indapamide as the independent comparative arms.

**Methods**

**Data sources and search strategy**

In our meta-analysis, we adhered to the PRISMA guideline strictly. The search strategy was designed by the first author and reviewed by another two authors. We searched for evidence in PubMed (1948–2017/Jan) and Embase (1980–2017/Jan), Google Scholar, the ScienceDirect, the metaRegister of Controlled Trials and the Cochrane Central Register of Controlled Trials using the following terms: (indapamide OR chlorthalidone) AND (hydrochlorothiazide) AND (systolic blood pressure OR diastolic blood pressure) AND (cardiovascular events OR antihypertensive efficacy OR heart rates OR electrolyte disturbance OR hypokalemia OR hyponatremia OR serum cholesterol OR blood glucose OR hyperglycemia OR hypercholesterolemia OR adverse effects). Moreover, references about the relevant reviews were also sought.

**Inclusion and exclusion criteria**

Trial inclusion criteria met the following criteria: (1) randomized clinical trial or double-blind controlled trial of thiazide-like or thiazide-type therapy in people with hypertension (SBP $\geq 140$ mmHg or DBP $\geq 90$ mmHg); (2) patients were allocated to 2 monotherapy thiazide or combined with other kind of antihypertensive drugs in fixed-dose arms; (3) duration of follow-up $\geq$ 4 weeks; (4) baseline washout and run-in phase of medication $\geq$ 1 week; (5) measurements of $\geq$ 1 of the following, systolic BP, diastolic BP, serum potassium, uric acid, serum cholesterol, glucose or heart rate. There were not yet enough trials including thiazide-like or thiazide-type diuretics for meta-analysis with the exception of hydrochlorothiazide, chlorthalidone and indapamide, so only trials including the comparison between hydrochlorothiazide and chlorthalidone or hydrochlorothiazide and indapamide were included. We excluded trials where subjects were predefined as responders or non-responders before the trial. If the study used the titration method in step-up protocols, we just extract the data using the initial doses. Studies using potassium supplementation were included, but step-down and drug withdrawal protocols were ineligible. Trials were also ineligible if participants were $< 18$ years old or had cirrhosis with ascites, type 1 or 2 diabetes, nephrotic syndrome, renal insufficiency, documented serum creatinine level $> 1.5$ times normal, history of ischaemic stroke, unstable angina or myocardial infarction within the past 6 months, cardiac failure, secondary hypertension, dementia or other cognitive impairment, pregnancy or lactating women. If the study condition permits, we used the blood pressure records via ambulatory blood pressure monitoring, if not, where resting BP measurements were available for $> 1$ time during a 24-hr period, the trough measurement, defined as 22–26 hr after dose, was used. When BP was recorded in multiple positions, sitting BP was used, unless variance data were only given for another position, in which case that position was used.
Study characteristics and quality assessment

The characteristics of studies [11–22] used for the meta-analysis were shown in Table 1. These studies were published from 1983 to 2016. A total number of 1580 patients from 12 trials were studied, in which 10 and 11 studies provided the data of systolic BP and diastolic reduction after treatment, respectively. In the thiazide-like diuretics group, we integrated the indapamide and chlorthalidone together. As there was lack of the head-to-head comparison trials between chlorthalidone and HCTZ, we found only three eligible trials used them in the monotherapy arm, while the remaining four trials compared the chlorthalidone and HCTZ both combined with another drug. All of the included studies were published in English. Score developed from the criteria of Jadad was utilized to assess study quality [23], which had a possible range from zero to five, including double blinding, randomization and drop-outs. It was defined as high quality if a study scored range from three points to five points.

Data extraction and statistical analysis

The primary end-point for our analysis was the systolic and/or diastolic BP reduction, the incidence of hypokalemia, hyponatremia and the change of serum total cholesterol and glucose throughout the different drug therapy. The changes of blood pressure, serum TG and glucose were computed as the difference in the BP at the final follow-up (or specific time-point if multiple time-points were provided) compared to the baseline or initial measurement. However, we analyse the incidence of hypokalemia using the dichotomous method. All data extracted from the 12 studies were recorded in Microsoft Excel before transfer to Review Manager version 5.0 program for analysis. Continuous variables were conveyed in the form of the mean and standard deviation (SD). Research results data whose means and SDs were unavailable were kicked out of the meta-analysis. Heterogeneity was calculated using the I-square statistic [24]. I-squared is the ratio of true heterogeneity to total variation in observed effect, and it will not be impacted by the size of studies. All analyses were initially carried out using a fixed-effects model. However, if heterogeneity across studies was observed, the analyses were carried out with a random-effects model. The random-effects model of inverse variance was used to calculate the odds ratio (OR) with 95% confidence interval (95% CI).

Results

Characteristics of studies

A total of 2485 records were found after searching in PubMed, Embase, Google Scholar and other databases. As some literatures did not provide free full texts, or the inappropriate comparative methods, only 45 full-text articles were reviewed after the first selection process (Fig. 1). In the second selection process, we have filtered out 33 articles, which do not contain complete available data; lower than 3 when doing quality score assessment according to Jadad score; do not have washout period. Ultimately, twelve studies were maintained in our re-analysis. The characteristic of included studies was described in this article (Table 1).

SBP reduction

In all of the included studies, 1307 patients from 10 trials provided data of systolic BP change from the baseline to the end-point of treatment period. Figure 2 shows the forest plot of different lowering systolic blood pressure efficacy between thiazide-like and thiazide diuretics. The final merged results show that thiazide-like diuretics (indapamide or chlorthalidone) will be significantly effective in lowering systolic BP(pooled effect size [95% CI]; −5.59 [−5.69, −5.49]; Heterogeneity: Chisq = 10.02, df = 9 [P = 0.35]; I² = 10%) than thiazide-type diuretics (hydrochlorothiazide).

DBP reduction

A meta-analysis of diastolic BP reductions between the thiazide-like and thiazide-type diuretics also showed a statistically meaningful result. As shown in Figure 3, among 1347 subjects from 11 trials, compared to hydrochlorothiazide, indapamide or chlorthalidone, can lower diastolic blood pressure more effectively (pooled effect size [95% CI]; −1.98 [−3.29, −0.66]; Heterogeneity: Tau² = 2.90; Chi² = 66.81, df = 10 (P < 0.00001); I² = 85%). The heterogeneity exists.

Incidence of hypokalemia

Four trials provided data of incidence of hypokalemia happened during or after the treatment period among 1050 subjects. It is shown in Figure 4, using thiazide-like diuretics indapamide or chlorthalidone, patients will have the same risks of hypokalemia with hydrochlorothiazide users (pooled effect size [95% CI]; 1.58 [0.80, 3.12], P = 0.16; Heterogeneity: Tau² = 0.13; Chi² = 4.10, df = 3 (P = 0.25); I² = 27%).

Incidence of hyponatremia

As shown in Figure 5, data from two trials showed the same risk of hyponatremia in users of thiazide-like group and thiazide-type group (pooled effect size [95% CI]; −0.14 [−0.57, 0.30], P = 0.54; Heterogeneity: Chi² = 0.13, df = 1 (P = 0.71); I² = 0%).

Total cholesterol and glucose

Four trials included data from 550 subjects; as shown in Figure 6, there were no statistically significant differences of total cholesterol between the two treatment groups (pooled effect size [95% CI]; 0.11 [−0.02, 0.24], P = 0.11; Heterogeneity: Tau² = 0.00; Chi² = 0.64,
| Study (author, year) | BP inclusion criteria | Quality score | Subjects (M) | Interventions | Duration of washout and run-in (weeks) | Duration of treatment (weeks) | Results measurement |
|----------------------|-----------------------|---------------|--------------|---------------|----------------------------------------|-----------------------------|-------------------|
| Radevski et al. (2002) | Sitting DBP 95-115 mmHg | 3 | 42 | 12.5 mg HCTZ vs. 2.5 mg IND | 3 | 12 | 24-hr ABPM |
| David et al. (1999) | Sitting DBP 95–105 mmHg | 3 | 39 | 25 mg HCTZ vs. 2.5 mg IND | 4 | 24 | Supine BP |
| GERARD et al. (1983) | Sitting DBP ≥ 95 mmHg | 3 | 24 | 50 mg HCTZ vs. 2.5 mg IND | 6 | 12 | Recumbent BP |
| A. Pareek et al. (2009) | SBP 140-179 mmHg or DBP 90-109 mmHg | 3 | 60 | 50 mg Metoprolol XL + 6.25 mg CTD vs. 50 mg Azilsartan medoxomil + 12.5 mg HCTZ | 1 | 8 | Seated BP; plasma potassium record |
| Leonetti et al. (2004) | Supine DBP 95–114 mmHg Supine SBP 161–209 mmHg | 4 | 354 | 25 mg HCTZ vs. 1.5 mg Indapamide SR | 4 | 12 | Supine BP |
| Kwon et al. (2012) | Never treated HTN(SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg) | 3 | 28 | 8 mg Candesartan + 25 mg HCTZ vs. 8 mg Candesartan + 12.5 mg CTD | 4 | 8 | Supine brachia BP |
| Michael et al. (2006) | SBP 140–179 mmHg or DBP 90–109 mmHg | 4 | 24 | Firstly: 12.5 mg CTD vs. 25 mg HCTZ; at week 4: force-titrated to 25 mg CTD vs. 50 mg HCTZ | 4 | 8 | 24-hr ABPM |
| Pareek et al. (2009) | SBP 140–179 mmHg or DBP 90–109 mmHg | 3 | 120 | 25 mg Losartan + 6.25 mg CTD vs. 25 mg Losartan + 12.5 mg HCTZ | 2 | 4 | Office blood pressure measurement |
| Senior et al. (1993) | DBP 95–120 mmHg | 4 | 40 | 25 mg HCTZ vs. 2.5 mg IND | 2 | 24 | Diastolic blood pressure |
| Siegel et al. (1992) | DBP 90–105 mmHg | 5 | 233 | 50 mg HCTZ vs. 50 mg CTD | 4 | 8 | 24-hr Holter monitoring and laboratory tests |
| Bakris et al. (2012) | Seated SBP 160–190 mmHg | 4 | 587 | 40 mg AZL-M/12.5 mg CTD vs. 40 mg AZL-M + 12.5 mg HCTZ | 4 | 4 | 24-hr mean BP |
| Anil K. Pareek et al. (2016) | Office SBP between 140 and 159 mmHg and DBP between 90 and 99 mmHg | 5 | 34 | 12.5 mg HCTZ vs. 6.25 mg CTD | 2 | 12 | 24-hr ambulatory blood pressure monitoring |
df = 3 (P = 0.89); I² = 0%). In the meta-analysis of change of serum glucose, we scanned seven trials included 804 subjects and the results also show no significant differences between thiazide-like and thiazide-type diuretics (pooled effect size [95% CI]; 0.13 [−0.16, 0.41], P = 0.39; Heterogeneity: Tau² = 0.07; Chi² = 16.35, df = 5 (P = 0.006); I² = 69%). The heterogeneity exists.

Heterogeneity and sensitivity analyses

We can believe that there is no heterogeneity exists in the analysis of systolic blood pressure reduction, incidence of potassium and total cholesterol because mild heterogeneity might account for I² is <30% of the variability in point estimates. However, in the meta-analysis of diastolic blood pressure reduction and the change of serum glucose, a notable heterogeneity is observed as I² is more than 50% [23]. To solve the problem, we have carried out the sensitivity analyses to exclude lower-quality studies, but there is no change of the results even when used another statistical model (data not shown).

Discussion

For meta-analysis, we searched for published thiazide diuretic-related studies that are three decades old. We extracted useful data from 12 included clinical trials. We reanalysed them and made a series of outcomes. The potent of thiazide-type and thiazide-like diuretics differed quite remarkably. We found out that thiazide-like diuretics, indapamide and chlorthalidone, have an advantage in...
lowering both systolic and diastolic blood pressure without significantly increasing the risks of hypokalemia and hyponatremia, or making a significant change of blood glucose and serum total cholesterol compared to the most prescribed thiazide-type diuretics such as hydrochlorothiazide.

Thiazide diuretics are the second most common type of antihypertensive drug. Therefore, it continues to be widely used in the treatment of hypertension. Whereas in the past half-century, there was few studies which compared the thiazide-type and thiazide-like diuretics directly in random trials. To provide more powerful evidence for clinical therapy, it is essential to make a comprehensive comparison between the most common prescribed antihypertensive agents. In consideration of the side effects of thiazide diuretics, the major concern might be electrolyte disturbance, serum glucose and total cholesterol. Due to the longer half-life of thiazide-like diuretics, risks of adverse events would be expected to increase, particularly the sodium and potassium homeostasis disorders. Our analysis made a comprehensive comparison of thiazide-type and thiazide-like diuretics to indicate that to achieve the same level of BP reduction, thiazide-like diuretics were not worse than thiazide-type diuretics in increasing risks of electrolyte disturbance.

Antihypertensive drugs are not only able to lower blood pressure, but there are many extra benefits in the cardiovascular system, such
as anti-inflammatory, anti-atherosclerosis, improve cardiac function and target organ protection. Several clinical studies had shown that low-dose diuretics could exert target organ protection effect when compared to other antihypertensive [25, 26].

Our findings of this study should be set in context of previous meta-analyses. In a dose-stratified meta-analysis and metaregression of 26 studies, Peterzan et al. [27] characterized the dose–response relationships for three commonly prescribed thiazide/thiazide-like diuretics, hydrochlorothiazide, chlorthalidone and bendroflumethiazide. He showed that chlorthalidone is more effective than hydrochlorothiazide both for BP reduction and biochemical outcomes. He also provided us the recommended dose and dose–effect relationship of these diuretics. In another large-scale meta-analysis published last year [28], thiazide-like diuretic could reduce risk of cardiovascular events and heart failure compared to thiazide-type diuretics. In this meta-analysis, the author used both placebo and other antihypertensive drugs as control arm, which would probably induce a biased baseline of the comparison. There was no detailed adverse effect analysis in this article. To avoid the difference in baseline, we only included studies that used both thiazide-like and thiazide-type diuretics as different arm but in the same trial. Additionally, this is the first meta-analysis, which highlighted the comparison of the major adverse effects of these two diuretics.

Electrolyte disturbance might be a major concern for prescribing thiazide diuretic. Jan C. performed a case–control study [29], which found an increase risk of hyponatremia in CTDN arm compared to HCTZ arm when given the equal dose, whereas there is no significantly increased incidence of hyponatremia in using CTDN compared with twice the dose of HCTZ per day (CTDN 12.5 mg/day vs. HCTZ 25 mg/day and CTDN 25 mg/day vs. HCTZ 50 mg/day). The dose–titrate of CND and HCTZ was mentioned in Berkris et al. study [11]. Therefore, a lower dose of CTDN required to achieve the same BP reduction as well as cardiovascular outcomes might also reduce the risk of hyponatremia. Likewise, in our study, we also performed the same results that using thiazide-like diuretic would not increase the incidence of hyponatremia compared to HCTZ treatment.

Several limitations exist in our meta-analysis. First, in two of the included studies, the original design is a crossover study, but to insure statistical robustness of the data in the presence of a possible carryover effect, we decided that only the data from those who complete the first active treatment period would be analysed. Secondly, we combined the indapamide and chlorthalidone together as one of the comparison arm without considering the variance between these two agents. On the other hand, we did not do the dose–response of the three drugs separately. This therefore means that we cannot neglect the error from different doses in the same group. Thirdly, some of our included studies were published long ago with the differences in inclusion and exclusion criteria, BP measurement techniques and drug formulation. Although the score of these trials (as assessed by Jadad criteria) is more than 3, the data from these studies will contribute to heterogeneity between studies. As there is lack of head-to-head comparative trials between chlorthalidone and HCTZ, we used the data from a combination of them with beta-blocker, ACEI or calcium channel blocker. The combination trials might make it hard to access the effects on blood pressure reduction efficacy, the risk of incidence of hypokalemia and hyponatremia and the change of blood glucose and total cholesterol of thiazide diuretics, which would make the results of the meta-analysis less compelling.

In summary, we performed a meta-analysis for the controversial clinical decision that whether thiazide-type or thiazide-like diuretics should be more prescribed as the initial antihypertensive therapy. Our analysis obtained the different efficacy of BP reduction and
biochemical outcomes when used the two kinds of drugs. It is recommended that further randomized controlled trials should be done to compare these two types of drugs. The available conclusion from our analysis suggests that thiazide-type diuretic should be replaced by the thiazide-like diuretic, which possesses higher BP reduction efficacy and no more risk of electrolyte disturbance and metabolic disorders.

Acknowledgements

This work was supported by National Natural Science Foundation of China (81500339, 81400195).

Conflict of interests

No potential conflict of interests were disclosed.

Authors’ contributions

W.J.L designed and conducted the analysis and wrote the manuscript. H.M and L.X.C collected and evaluated the data. J.J.Y and W.J.Y contribute to the design, analysis and revised the manuscript. J.J.Y is the guarantor of the work and takes the responsibility and accuracy for the integrity of the results.

References

1. Ernst ME, Moser M. Use of diuretics in patients with hypertension. N Engl J Med. 2009; 361: 2153–64.
2. Messerli FH, Bangalore S. Half a century of hydrochlorothiazide: facts, fads, fiction, and follies. Am J Med. 2011; 124: 896–9.
3. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311: 507–20.
4. Tziomalos K, Athyros VG, Mikhailidis DP, et al. Hydrochlorothiazide vs. chlorothalidone as the optimal diuretic for the management of hypertension. Curr Pharm Des. 2013; 19: 3766–72.
5. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorothalidone: evidence supporting their interchangeability. Hypertension (Dallas, Tex: 1979). 2004; 43: 4–9.
6. Perry HM Jr, Smith WM, McDonald RH, et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study. Stroke. 1989; 20: 4–13.
7. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991; 265: 2525–64.
8. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288: 2981–97.
9. Madkour H, Gadallah M, Riveline B, et al. Indapamide is superior to thiazide in the preservation of renal function in patients with hypertension. Am J Cardiol. 1996; 77: 23b–5b.
10. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008; 358: 1867–98.
11. Bakris GL, Sica D, White WB, et al. Antihypertensive efficacy of hydrochlorothiazide vs chlorothalidone combined with lisartan medoxomil. Am J Med. 2012; 125: 1229.e1–e10.
12. Pareek A, Basavanagowdappa H, Zawar S, et al. A randomized, comparative study evaluating the efficacy and tolerability of losartan-low dose chlorothalidone (6.25 mg) combination with losartan-hydrochlorothiazide (12.5 mg) combination in Indian patients with mild-to-moderate essential hypertension. Expert Opin Pharmacother. 2009; 10: 1529–36.
13. Pareek A, Zawar SD, Salagre SB, et al. Antihypertensive efficacy of metoprolol XL/low dose chlorothalidone (6.25 mg) combination: a randomized, comparative study in Indian patients with mild-to-moderate essential hypertension. Eur J Med Res. 2009; 14: 297–303.
14. Ernst ME, Carter BL, Goertd CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorothalidone on ambulatory and office blood pressure. Hypertension (Dallas, Tex: 1979). 2006; 47: 352–8.
15. Emeriau JP, Knauf H, Pujadas JO, et al. A comparison of indapamide SR 1.5 mg with both amiodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. J Hypertens. 2001; 19: 343–50.
16. Spence JD, Huff M, Barnett PA. Effects of indapamide versus hydrochlorothiazide on plasma lipids and lipoproteins in hypertensive patients: a direct comparison. Can J Clin Pharmacol. 2000; 7: 32–7.
17. Siegel D, Huilley SB, Black DM, et al. Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men. JAMA. 1992; 267: 1083–9.
18. Plante GE, Robillard C. Indapamide in the treatment of essential arterial hypertension: results of a controlled study. Curr Med Res Opin. 1983; 8(Suppl 3): 59–66.
19. Senior R, Imbs JL, Bory M, et al. Indapamide reduces hypertensive left ventricular hypertrophy: an international multicenter study. J Cardiovasc Pharmacol. 1993; 22 (Suppl 6): S106–10.
20. Radevski IV, Valchanova ZP, Candy GP, et al. Comparison of indapamide and low-dose hydrochlorothiazide monotherapy in black patients with mild to moderate hypertension. S Afr Med J. 2002; 92: 532–6.
21. Kwon BJ, Jang SW, Choi KY, et al. Comparison of the efficacy between hydrochlorothiazide and chlorothalidone on central aortic pressure when added to candesartan in treatment-naïve patients of hypertension. Hypertens Res. 2013; 36: 79–84.
22. Pareek AK, Messerli FH, Chandurkar NB, et al. Efficacy of low-dose chlorothalidone and hydrochlorothiazide as assessed by 24-h ambulatory blood pressure monitoring. J Am Coll Cardiol. 2016; 67: 379–89.
23. Franse LV, Pahor M, Di Bari M, et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension (Dallas, Tex: 1979). 2000; 35: 1025–30.
24. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17: 1–12.
25. Mourad JJ, Le Jeune S. Evaluation of high dose of perindopril/indapamide fixed
combination in reducing blood pressure and improving end-organ protection in hypertensive patients. *Curr Med Res Opin*. 2009; 25: 2271–80.

26. Gosse P. Perindopril/indapamide combination in the first-line treatment of hypertension and end-organ protection. *Expert Rev Cardiovasc Ther*. 2006; 4: 319–33.

27. Peterzan MA, Hardy R, Chaturvedi N, *et al.* Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. *Hypertension* (Dallas, Tex: 1979). 2012; 59: 1104–9.

28. Olde Engberink RH, Frenkel WJ, van den Bogaard B, *et al.* Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis. *Hypertension* (Dallas, Tex: 1979). 2015; 65: 1033–40.

29. van Blijderveen JC, Straus SM, Rodenburg EM, *et al.* Risk of hyponatremia with diuretics: chlorthalidone versus hydrochlorothiazide. *Am J Med*. 2014; 127: 763–71.